Tern
VC Fund
London, United Kingdom
Tern is a VC fund in London focused on Software and Information Technology. Tern provides venture capital to exciting, high growth IoT innovators in Europe. They provide more than just funding. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. They empower business owners to fulfil their potential for fast growth, market leadership and strong exit multiples.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Tern invests in
Stages Tern invests in
Countries Tern invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.2M–$1.4M
- Venture - Series Unknown
- $2M–$2.9M
Investment Focus
Industry
- Software 4 (19%)
- Information Technology 3 (14%)
- Medical 2 (10%)
- Health Care 2 (10%)
- Machine Learning 2 (10%)
Stage
- Funding Round 6 (29%)
- Venture - Series Unknown 3 (14%)
- Seed 2 (10%)
- Convertible Note 2 (10%)
- Series A 1 (5%)
Country
- United Kingdom 6 (29%)
- United States 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Albert E Sisto
Chief Executive Officer
|
Chief Executive Officer | Total investments: 1 | Find email | |
Bruce Leith
Founder, Business Development and Investment Director
|
Founder, Business Development and Investment Director | Total investments: 0 | Find email | |
Matthew Scherba
Partner and Investment Director
|
Partner and Investment Director | Total investments: 0 | Find email | |
Sarah Payne
Finance Director & Chief Financial Officer
|
Finance Director & Chief Financial Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Data tech innovator Talking Medicines, based in Glasgow and London, uses advanced AI and ML to provide pharmaceutical companies with real-time data intelligence. The company uses a collection of AI, ML and NLP tech tools to capture and structure the voice of the patient from real world conversations and behaviours at home. Through mapping thepatient voice from social media and connected devices to regulated medicine information, the company is able to build data points to deliver trends and patterns of patient sentiment across medicines. This intelligence embraces regulatory compliance enabling marketing in pharmaceutical companies to measure patient confidence by medicine and in turn action the levers for share growth. | $363.7K / Convertible Note / May 26, 2026 | ||
| FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. | $20M / Series B / Aug 11, 2022 | ||
| Data tech innovator Talking Medicines, based in Glasgow and London, uses advanced AI and ML to provide pharmaceutical companies with real-time data intelligence. The company uses a collection of AI, ML and NLP tech tools to capture and structure the voice of the patient from real world conversations and behaviours at home. Through mapping thepatient voice from social media and connected devices to regulated medicine information, the company is able to build data points to deliver trends and patterns of patient sentiment across medicines. This intelligence embraces regulatory compliance enabling marketing in pharmaceutical companies to measure patient confidence by medicine and in turn action the levers for share growth. | $2M / Venture - Series Unknown / Feb 01, 2022 | ||
| Konektio is a dedicated M2M and IoT company which uses the best technology to deliver performance and solutions quickly and cost effectively. When you enquire we will need to visit you to discuss how to maximise the Konektio benefits for your particular business, whether OEM or End User, and also the type of devices (things) that you wish toconnect to. Our experience will help you to get the most out of any investment. | $2.8M / Venture - Series Unknown / Dec 21, 2021 | ||
| Device Authority provides simple, innovative solutions to address the challenges of securing the Internet of Things (IoT). We help our customers simplify the process of establishing a robust, end-to-end security architecture within the IoT and deliver efficiencies at scale through security automation.IoT brings new security challengesintroduced by the scale and pace of adoption, as well as the physical consequences of compromised security. These challenges cannot be effectively addressed by traditional Information Technology (IT) security solutions. The Device Authority IoT security platform is purpose-built to address these challenges through automated device provisioning, credential management, secure updates and policy-driven data encryption.The IoT promises countless efficiencies, increased competitiveness, improved customer service and even brand new market opportunities. However, deploying strong security is hard and always has been. Deploying strong IoT security is even harder. According to Gartner, by 2020, around 25% of all identified security breaches will involve IoT. To address this, Device Authority introduces a new paradigm of IoT Security Automation that accelerates and simplifies the deployment of strong IoT security.Advanced, policy driven security automation is critical for industrial, healthcare, transportation and other large scale security sensitive IoT environments. Our patented dynamic key technology provides the essential device-based trust anchor for IoT devices, enabling policy-driven provisioning, access control and data protection for mission-critical IoT applications and services.The dedicated IoT Security entity was launched in September 2014 when the Cryptosoft technology was spun out with backing from the current investors. In April 2016 Cryptosoft acquired DeviceAuthority Inc, and subsequently the changed its name to Device Authority Ltd, headquartered in the UK and with a technical development center based in Fremont, CA. | $2.9M / Venture - Series Unknown / Dec 02, 2021 | ||
| Data tech innovator Talking Medicines, based in Glasgow and London, uses advanced AI and ML to provide pharmaceutical companies with real-time data intelligence. The company uses a collection of AI, ML and NLP tech tools to capture and structure the voice of the patient from real world conversations and behaviours at home. Through mapping thepatient voice from social media and connected devices to regulated medicine information, the company is able to build data points to deliver trends and patterns of patient sentiment across medicines. This intelligence embraces regulatory compliance enabling marketing in pharmaceutical companies to measure patient confidence by medicine and in turn action the levers for share growth. | $1.4M / Seed / Nov 04, 2020 | ||
| Founded in 2016 with an objective of enabling affordable low power IoT connectivity using LEO Satellites. Wyld Connect leverages low power wireless technology and low earth orbiting satellites using LoRaWAN. Wyld enables affordable IoT connectivity across the globe in areas where there is no wireless coverage.Based in Cambridge UK and listed onthe NASDAQ FN exchange, Wyld Networks are an energetic, creative technology company with a pedigree in wireless electrical engineering.Experts in LPWAN, Wyld offers innovative hardware, software and data plans to deliver the best solution for IoT connectivity problems in any given environment. | $490.1K / Convertible Note / May 12, 2020 | ||
| Founded in 2016 with an objective of enabling affordable low power IoT connectivity using LEO Satellites. Wyld Connect leverages low power wireless technology and low earth orbiting satellites using LoRaWAN. Wyld enables affordable IoT connectivity across the globe in areas where there is no wireless coverage.Based in Cambridge UK and listed onthe NASDAQ FN exchange, Wyld Networks are an energetic, creative technology company with a pedigree in wireless electrical engineering.Experts in LPWAN, Wyld offers innovative hardware, software and data plans to deliver the best solution for IoT connectivity problems in any given environment. | $905.9K / Convertible Note / Nov 01, 2019 | ||
| FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. | $5M / Series A / Oct 30, 2019 | ||
| FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. | $1.4M / Oct 30, 2018 | ||
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tern invest in?
Tern invests primarily in Software, Information Technology and Medical startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 21 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tern's check size?
Tern typically joins rounds of $1.2M–$1.4M at Seed and $2M–$2.9M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tern participates in.
How do I contact Tern?
Public channels for Tern include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tern?
The team at Tern includes Albert E Sisto (Chief Executive Officer), Bruce Leith (Founder, Business Development and Investment Director) and Matthew Scherba (Partner and Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
